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Abstract
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects about five million people
worldwide. Diagnosis remains clinical, based on phenotypic patterns. The discovery of laboratory markers that will enhance
diagnostic accuracy, allow pre-clinical detection and tracking of disease progression is critically needed. These biomarkers
may include transcripts with different isoforms.
Methodology/Principal Findings: We performed extensive analysis on 3 PD microarray experiments available through GEO
and found that the RNA splicing gene SRRM2 (or SRm300), sereine/arginine repetitive matrix 2, was the only gene
differentially upregulated among all the three PD experiments. SRRM2 expression was not changed in the blood of other
neurological diseased patients versus the healthy controls. Using real-time PCR, we report that the shorter transcript of
SRRM2 was 1.7 fold (p=0.008) upregulated in the substantia nigra of PDs vs controls while the longer transcript was 0.4
downregulated in both the substantia nigra (p=0.03) and amygdala (p=0.003). To validate our results and test for the
possibility of alternative splicing in PD, we performed independent microarray scans, using Affymetrix Exon_ST1 arrays, from
peripheral blood of 28 individuals (17 PDs and 11 Ctrls) and found a significant upregulation of the upstream (59) exons of
SRRM2 and a downregulation of the downstream exons, causing a total of 0.7 fold down regulation (p=0.04) of the long
isoform. In addition, we report novel information about hundreds of genes with significant alternative splicing (differential
exonic expression) in PD blood versus controls.
Conclusions/Significance: The consistent dysregulation of the RNA splicing factor SRRM2 in two different PD neuronal
sources and in PD blood but not in blood of other neurologically diseased patients makes SRRM2 a strong candidate gene
for PD and draws attention to the role of RNA splicing in the disease.
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Introduction
The diagnosis of Parkinson’s disease (PD) remains purely
clinical and is based on the phenotypic expression of three
cardinal clinical signs (bradykinesia, tremor and rigidity) in the
absence of symptoms and signs indicative of other neurological
diseases. Genome-wide transcription analysis of biological material
(i.e. human, animal tissues, cell cultures) has shown promise in
identifying disease-relevant biomarkers [1]. Postmortem human
brain expression profiling has shown significant changes in PD
versus healthy states [2,3,4,5,6,7,8,9,10]. A single study looking at
expression patterns in peripheral venous blood samples of patients
with movement disorders and control subjects has provided some
preliminary insight on possible blood biomarker candidates for PD
diagnosis [11].
We hypothesized that computational analysis of multiple PD
microarray data can be used to identify certain sets of PD-
associated marker genes based on gene expression patterns.
Therefore, we thoroughly analyzed three publicly available PD
datasets generated from a rotenone-treated neuroblastoma
line[12], postmortem substantia nigra from PD patients and
controls[2], and lymphocytes from PD patients and controls[11].
While this approach deals with a huge variability factor, the
strength of the approach lies in using evidence in multiple PD
datasets that may be very different in etiology, cause, and tissue
source. In summary, we hypothesized that interrogating publicly
available PD transcriptome-wide expression datasets from differ-
ent tissue sources would identify lead candidate genes.
In this study, we identified the RNA splicing factor SRRM2 (or
SRm300), serine/arginine (SR) repetitive matrix 2 as differentially
expressed in multiple gene expression datasets. Such an SR
protein binds both to sequence elements on the pre-mRNA and to
other components of the spliceosome. As a result, multimolecular
complexes that interact with pre-mRNA at multiple sites are
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sequences in the excision-splicing event[13]. Driven by the
biological function of SRRM2, we investigated the possibility of
alternative splicing of 1) this candidate gene in two different brain
regions from PD patients and controls, and 2) global transcripts in
PD blood samples and controls. We found that SRRM2 has
differential splicing in PD substantia nigra, amygdala, and
leukocytes of sporadic PD patients. In addition to identifying
SRRM2 as alternatively spliced and as a potential biomarker for
PD, we report here 3 general interesting findings. First, there is an
interesting overlap in differential gene expression between the
brain (substantia nigra) and blood in PD, which highlights the
credibility for using blood to find biomarkers in PD. Second, there
are 35 genes (including SRRM2) differentially expressed in PD
blood in both our new blood study and the Scherzer blood
study[11]. These may all be worth further scrutiny as potential
blood biomarkers for PD. Third, there are hundreds of genes
(including SRRM2) with differential alternative splicing in PD
blood samples relative to controls. Therefore, there is a prevalent
phenomenon of alternative splicing in PD that calls for more study
and investigation.
Results
SRRM2 Is the Only Differentially Expressed Gene in All 3
PD Expression Datasets
We performed extensive analysis on three different publicly
available microarray experiments on PD: (A) Twenty-two chips
from the substantia nigra in postmortem brain of PD patients and
controls [2], (B) 21 chips on one to four week rotenone-treated
neuroblastoma cells [12] (an in vitro model of PD), (C) 105 chips on
peripheral blood of PD versus healthy and neurological disease
control subjects [11]. There were 174 transcripts corresponding to
160 genes that overlapped in at least 2/3 PD experiments.
Representative genes are shown in the heatmap (Figure 1A). The
complete list of differentially expressed overlapping genes between
any 2 of the 3 PD experiments is presented in Table S1. The RNA
splicing gene SRRM2, (serine/arginine repetitive matrix 2) was the
only gene differentially upregulated in all three PD experiments
(Figure 1B). SRRM2 transcript was 1.77 fold (p,0.01) upregulated
in the substantia nigra of PD patients versus controls. SRRM2
transcript was 1.44 fold (p,0.05) upregulated in the 4 wk rotenone
treated cells versus the controls. SRRM2 transcript was 1.27 fold
(p,0.05) upregulated in peripheral blood of PD patients versus
healthy controls and was unchanged in the blood of neurological
disease patients versus the healthy controls.
SRRM2 Isoforms Are Both Differentially Expressed in PD
but in Opposite Directions
SRRM2 has one long isoform (16 exons) and 3 short isoforms
(,11 exons). See Figure 2A. Using real-time PCR on postmortem
substantia nigra (SN) and amygdala from 10 PD patients versus 10
controls, we found that the shorter transcript of SRRM2 was
significantly upregulated (FC=1.7, p=0.008) in the SN (as in the
microarrays) but unchanged in the amygdala (AMG) of PD
patients. Interestingly, the longer transcript of SRRM2 was
significantly 0.4 downregulated in both the SN (p=0.03) and
Amygdala (p=0.003) of PD patients (Figure 2B).
Splicing Analysis Confirms Isoform Switching of SRRM2
and Reveals High Alternative Splicing Phenomenon in PD
Using new Exon array profiling on peripheral blood that we
collected from 17 PD patients and 11 controls (GSE 18838), we
looked for genes with differential splicing. We identified exons that
have statistically significant changes in inclusion rates (relative to
the gene level) between PDs and controls. Consistent with rt-PCR
results, we found that SRRM2 in PD switches from basal
transcript levels of SRRM2 to high expression of the short isoform
and low expression of the long isoform. Interestingly, there was a
strikingly significant elevation of overall gene splicing in PD blood
compared to controls as shown by 218 genes (listed in Table S2),
each consisting of exons that have differential expression within
the same gene between PDs and controls. Figure 3 shows the
differential exonic expression of SRRM2 and 3 other genes. These
4 genes are the ones that overlapped between the 218 differentially
spliced genes in our new dataset and the 35 genes that we
validated from the Scherzer blood microarray [11] (as explained in
the next section and shown in Figure 4B). Gene Ontology
classification of the 218 genes with significant splicing events
grouped 112 of the 218 genes into one molecular significant
function, protein binding, with corrected p-value =0.004, (listed in
Table S3).
Comparison with Earlier Blood Expression Study
Our new microarray experiment examining global gene
expression in peripheral blood samples from 17 PD patients and
11 controls revealed 58 genes differentially expressed by at least
2.0 fold change (p,0.05) (listed in Table S4). The top 10 genes (FC
of at least 2.5) are shown in Figure 4A. We compared the genes
differentially expressed (FC=1.2 p,0.05) in our data to the ones
in the Scherzer data [11]. Interestingly, we found an overlap of 35
transcripts shown in Figure 4B, including the downregulated
Bcl11B which had previously been validated by real-time PCR
[11]. That is out of ,150 transcripts that were differentially
expressed in either one of the two PD blood expression studies
(,40,000 transcripts queried per chip), 35 genes, including
SRRM2, were common to both studies. Note that in our
microarray data, not all genes including SRRM2 passed the
threshold when we stratified by gender as shown in Supplementary
Figure S1. This is most likely due to loss of power as the number of
replicates became small after stratification.
Discussion
We interrogated multiple datasets from different tissue sources
and identified a potential molecular marker SRRM2 (Figure 1B).
While SRRM2 was the only gene that stood out as differentially
expressed in all 3 PD public datasets, there were other genes that
overlapped in 2 out of the 3 PD experiments (Figure 1A and Table
S1). Among the intriguing overlaps that emerged from our analysis
are the following: SNCA (alpha-synuclein), a PD-associated gene
involved in microglial cell activation and synaptic transmission,
was significantly downregulated in both the substantia nigra and
blood in PD patients versus controls. BCL11B, which was
previously shown by microarrays and rt-PCR to be downregulated
in PD blood[11] was also downregulated in rotenone-treated
neuroblastomas, and so was the creatine neurotransmitter
transporter SLC6A8. The transcription factor SOX11 and the
endoplasmic reticular protein OLFM1, both involved in nervous
system development, as well as CNTN4 (contactin4) involved in
axonal guidance and brain development, were all downregulated
in both the substantia nigra and rotenone-treated neuroblastomas.
SRRM2 plays an important role in pre-mRNA splicing and has
recently been shown to play a role in cell migration [14]. Recent
analyses suggest that at least 75% of multi-exon genes in the
human genome are subject to alternative splicing [15]. This form
of pre-mRNA post-transcriptional modification has the potential
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activities [16]. Some genes generate tens of thousands of
functionally distinct proteins [17]. Splice variants from the same
gene can produce proteins with distinct properties and different
(even antagonistic) functions [18] [19]. A number of genetic
mutations involved in human disease have been mapped to
changes in splicing signals or sequences that regulate splicing [20].
In a very relevant context, splice isoform ratios have been
proposed to be robust biomarkers for physiological conditions
[21]. Thus, an understanding of changes in splicing patterns is
critical to a comprehensive understanding of the biological
regulation and underlying mechanism of PD.
To date, all of the global expression studies in PD have looked
at a single transcript per gene, although most genes have multiple
transcripts generated by alternative splicing. Alternative pre-
mRNA splicing may be used as a mechanism of gene
regulation[22]. The primary long transcript can be processed in
many different ways by alternative usage of exons. Regulatory
Figure 1. Heat map and venn diagrams of differentially expressed genes overlapping in multiple PD studies. A. Shown are the fold
change expression levels of genes differentially expressed in at least 2/3 PD studies: (1) up in both the substantia nigra (SN) and 4-wk rotenone-
treated cells (RT), (2) down in substantia nigra and blood, (3) down in 4-wk rotenone-treated cells and blood. Arrows point to selected upregulated
(red) and downregulated (blue) genes. B. Differentially expressed genes determined by our analysis of 3 different microarray experiments on PD,
each from a different tissue source, were compared to find common downregulated (left) and upregulated (right) transcripts. A 1.2 fold change and
p,.05 significance cut-offs were used. No multiple correction was employed.
doi:10.1371/journal.pone.0009104.g001
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PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9104Figure 2. Alternate isoforms of SRRM2 with different number of exons and different expression levels in postmortem PD brain. A.
Two main splice variants of SRRM2 differ at their 39 end. The longer SRRM2 isoform contains 15 exons and the shorter isoform contains 11 exons. B.
SRRM2 isoforms were differentially expressed in postmortem PD brain regions. The shorter transcript of SRRM2 was 1.7 fold (p=0.008) upregulated in
the SN of PDs versus controls while the longer transcript was 0.4 fold downregulated in both the SN (p=0.03) and Amygdala (p=0.003) of PDs versus
controls.
doi:10.1371/journal.pone.0009104.g002
Figure 3. Differential Exonic expression in PD Blood. Splicing Analysis reveals significant differential exonic expression within 218 genes
(p,0.05 with Benjamini Hochberg FDR correction). Shown here are SRRM2, ADIPOR1, TKT, and SLC4A1, all four genes were also differentially
expressed in the Scherzer blood data (p,0.05 with no multiple correction). Each probeset represents an exon. Note that in SRRM2, the 59 exons are
upregulated while the downstream exons are downregulated in PD patients versus controls.
doi:10.1371/journal.pone.0009104.g003
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numerous pre-mRNAs, often occurring to coordinate changes in
protein isoform expression and function. While many modifica-
tions resulting from alternative splicing are subtle, they can affect
major signaling properties of the nervous system, such as ion
channel features, half-life of proteins and gain or loss in receptor
function[23]. Multiple intrinsic and environmental stimuli can
affect splicing. In addition, splicing errors are associated with a
wide variety of diseases including ALS[24,25], Alzheimer’s
disease[26,27,28] and PD[28,29,30,31,32,33]. There is currently
little information on the prevalence, type, and significance of
splicing of genes in PD in the literature.
The RNA splicing factor SRRM2 which we found as
differentially expressed in multiple public PD datasets had
alternative splice forms in two brain regions, substantia nigra and
amygdala, from PD patients (Figure 2). Our global splicing analysis
of blood samples from 17 PD patients and 11 healthy controls
showed that SRRM2 has differential exonic expression, with the 59
exons over-expressed and the 39 exons down-regulated in PD
relative to controls (Figure 3). Interestingly, there were hundreds of
genes with significant changes in exonic expression in PD blood
versus controls (S2). Currently, we know only a few of the
transacting splice factors that control alternative splicing of synaptic
protein pre-mRNAs (reviewed in [34]). Future studies aimed at
identifying these factors should reveal new signaling pathways that
orchestrate changes in alternative splicing of multiple pre-mRNAs
to control neuronal excitability and synaptic efficacy.
The final outcome is that differential expression and alternative
splicing of SRRM2 potentially invokes high levels of alternative
splicing in the genome of PD patients. While experimental
validation is needed to support our conclusion, the phenomena of
an isoform-dependent regulation of pre-mRNA splicing already
exists[35]. While our splicing analysis was done in blood samples,
we anticipate that such high levels of alternative splicing, at the
transcriptome level, is also present in the brain of PD patients
because that the same pattern of SRRM2 splicing and dys-
regulation is evident in the substantia nigra and amygdala of PD
patients (Figure 2B).
Importantly, the binding of serine arginine proteins such as
SRRM2 to their degenerate recognition exonic sequences is
Figure 4. Differential gene expression in 2 PD blood studies. A. Shown are top 10 genes differentially expressed by at least 2.5 fold in PD
blood versus controls according to analysis of our new expression arrays (p,0.05 with no multiple correction). B. 35 differentially expressed
transcripts by at least 1.2 fold overlap between our new PD blood profiling and the Scherzer blood dataset (p,0.05 with no multiple correction).
doi:10.1371/journal.pone.0009104.g004
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tion, for example, certain sequence elements are recognized only
at higher SR protein concentration[36]. Therefore, an over-
expression of SRRM2 in PD brain and blood may lead to an
increased concentration if SRRM2 protein levels enabling slicing
events to take place. Further studies will be needed to understand
how SRRM2 itself is alternatively spliced and dynamically
expressed in PD and to determine whether splicing is prevalent
in the substantia nigra of PD patients and how it may play a role in
the development of PD.
Methods
Analysis of 3 Previous PD Microarray Datasets
We performed extensive analysis on three different publicly
available microarray experiments on PD: (A) Twenty-two chips
from the substantia nigra in postmortem brain of PD patients and
controls [2] (GEO Accession: GSE7621), (B) 21 chips on one to
four week rotenone-treated neuroblastoma cells [12], an in vitro
model of PD (GEO Accession: GSE4773), (C) 105 chips on
peripheral blood of PD versus healthy and neurological disease
(non-PD) control subjects[11] (GEO Accession: GSE6613). All
151 raw expression files were normalized using GC-RMA
processor. All normalized expression data was analyzed using
GeneSpring software. Following normalization one-way analysis of
variance was performed for each gene to identify statistically
significant gene expression changes. Two criteria were used to
determine whether a gene was differentially expressed: fold change
of 61.2 and p value ,.05 using a two-tailed distribution. No
correction for multiple comparisons was done. While a value of 1.2
is considered a low cut-off for fold change in microarrays, it is an
accepted cut-off which with statistical significance, is likely to be
validated by real-time PCR[37]. Lists of differentially expressed
genes from different experiments were compared within Gene-
Spring and displayed as Venn diagrams to show overlapping and
non-overlapping genes (Figure 1). The complete list of overlapping
genes is shown in Table S1.
Real-Time PCR of SRRM2 Isoforms in Postmortem SN and
AMG
Tissue samples from 10 sporadic PD patients and 10controls (5
male, 5 female, mean age 84.25-SD 6.4) were examined.
Demographics and clinical details for PD patients are provided in
Table S5.Allcontrols had normal brainpathology with no evidence
orhistoryofneurodegenerative processes.TotalRNAwasextracted
from 100 mg of brain tissue (provided by the University of Miami
Brain Bank) using TRIzol Reagent (Invitrogen, Carlsbad, CA). For
each extraction RNA concentration and integrity was determined
by an Agilent Nanodrop Spectrophotometer and Agilent BioAna-
lyzer respectively, and cDNA was synthesized using high capacity
cDNA kit (Applied Biosystems, Foster City, CA). SRRM2
expression level was measured in each sample by real-time PCR
using the ABI 7900HT thermocycler. SRRM2 expression levels
were normalized to those of the internal reference 18S rRNA
(Hs99999901_s1). All samples were run in duplicates. cDNA was
amplified using TaqMan Universal PCR master mix reagent
(Applied Biosystems, Foster City, CA) at the following conditions:
10 minutes at 25uC, 120 minutes at 37uC, and 5 seconds at 85uC.
The two target SRRM2 cDNAs were amplified using TaqMan
assay (,120 bp sequence) Hs00909897_m1, interrogating exon 2–
3 boundary, and Hs00249492_m1, interrogating exons 12–13
boundary. Data was analyzed using software RQ manager 1.2 from
Applied Biosystems, CA.
Subject Recruitment
Human subjects were recruited at the outpatients department of
the Movement Disorders Division of the Department of
Neurology, University of Miami, Miller School of Medicine.
The Institutional Review Board of The University of Miami
approved this study. Written informed consent was obtained from
all study participants. Whole blood samples were collected under
approved ethical committee protocols from the Movement
Disorders Division of the Department of Neurology, University
of Miami, Miller School of Medicine. All patients were diagnosed
by at least 2 board-certified and fellowship-trained movement
disorders neurologists according to the UK Society Brain Bank
Criteria for the diagnosis of PD [38]. Control subjects were
spouses or caregivers of patients who had no personal or family
history of neurodegenerative diseases. Exclusion criteria for all
study subjects were age under 21 years, hematologic malignancies
or coagulopathies, known severe anemia (hematocrit .30), and
known pregnancy. Clinical data of subjects is summarized in
Table S6.
RNA Isolation for Exon Arrays
RNA isolation was performed using the Preanalytix Paxgene
blood RNA kit, and small RNAs were extracted using a modified
RNEasy protocol. Paxgene blood RNA tubes were centrifuged to
form a pellet. Then an enzymatic digestion step followed by a
filtration step was used to remove gDNA and cell debris. Ethanol
was added to the lysate and passed through a silica membrane.
The flow through from this step was collected for use in the small
RNA extraction. After a series of washes and a DNase step, RNA
was eluted in 60 mL of RNase/DNase free water. Then 1.4x
volumes of ethanol was added to the collected flow through and
passed through an RNeasy silica gel membrane. Small RNAs were
eluted in 40 mL of RNAse/DNase free water. RNA was analyzed
and quantified by digital electrophoresis (Agilnet Bioanalyzer,
Agilent Technologies) and UV spectrophotometry (Nanodrop
1000, Thermo Scientific). 28 (17 PDs and 11 controls) samples
passed the quality control (RIN.5) and concentration require-
ment for the Exon microarrays, while 21 samples (13 PDs and 8
controls) passed those requirements for the miRNA TLDA cards.
All the RNA samples used in our expression study had RIN values
between 7 and 9.
Exon Arrays: Global Transcription Analysis and Splicing
Analysis
1 microgram of RNA (excluding small RNAs) from each of the
28 subjects (17 PDs and 11 controls) was labeled for hybridization
to Affymetrix Human Exon Arrays covering known cDNAs, ESTs,
and predicted gene structure sequences, using standard Affymetrix
protocols. Briefly, labeled samples were added to arrays, and
arrays were hybridized for 17 hours at 45uC. The arrays were
stained and washed according to Affymetrix Fluidics Station 450
protocol (FS450_0001). Hybridization was documented using a
GeneChip Scanner 3000 7G and validated with Affymetrix
Microarray Suite version 5.0 (MAS 5.0) software. Pearson
correlation coefficients demonstrated high reproducibility. Two
samples (CT#3, PD#19) were acting as outliers and were
therefore excluded from the analysis. Subsequent statistical
analysis was performed using GeneSpring GX 10 software (Silicon
Genetics, Redwood City, CA). Normalized expression values were
calculated by the GC-Robust Multi-array Average (GC-RMA)
method. The resultant signal information was analyzed using one-
way analysis of variance (ANOVA) (p,0.05), assuming normality
and equal variances. No correction for multiple comparisons was
SRRM2 & Alt. Splicing in PD
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likelihood of observing a specific fold change to the likelihood of
observing a fold change of 1, was active during this test.
Hierarchical clustering analysis was performed using the Gene-
Spring 10 software (Silicon Genetics, Inc., Redwood city, CA,
USA) to generate dendrograms representing each functional
category of genes based on their expression profiles. Heat maps
were generated by dividing each measurement by the 50.0th
percentile of all measurements in that sample, then setting the
average value of expression level for each gene across the samples
to 1.0, and plotting the resulting normalized signal value for each
sample (values below 0.01 were set to 0.01). The list and the order
of various genes in which they appear in the heatmaps can be
viewed in tabular form.
For splicing analysis, core transcripts were normalized via
RMA16 and filtered for detection above background level
(p,0.00025). Splicing ANOVA was then performed with a
p,0.05 and a Benjamini Hochberg FDR correction. The resulting
transcripts were further filtered by a splicing index of 0.87 to yield
a total of 218 transcripts with exons with statistically significant
changes in inclusion rates (relative to the gene level) between PDs
and controls. The output of 218 alternatively spliced transcripts
were subjected to Gene Ontology (GO) analysis within Gene-
Spring X to find any significant over-representation of molecular
category. A statistical test assigns a p-value to each category. All
data is MIAME compliant and all raw.CEL files from the 28 exon
arrays are deposited in NCBI’s GEO database (GSE 18838), a
MIAMI compliant database.
For confirmation of gender in our cohort, we looked at the
expression levels of 18 Y-linked genes and confirmed that they
were highly expressed in the male subjects. (See Supplementary
Figure S2).
Supporting Information
Figure S1 Stratifying microarray data by gender. Venn
diagrams show genes differentially expressed (p,.05) by 1.2 fold
(A) or 2.0 fold (B) in females only, males only, or both females and
males. No multiple correction was done.
Found at: doi:10.1371/journal.pone.0009104.s001 (6.06 MB TIF)
Figure S2 Confirmation of gender of microarray cohort by
expression of 18 Y-linked genes. Box plot shows average
expression levels of 18 Y-linked genes in each chip. Males show
high expression of Y chromosome genes. The 18 genes used are
RPS4Y1,ZFY, PCDH11Y, TBL1Y, PRKY, TTTY12, USP9Y,
TMSB4Y, NLGN4Y, RPS4Y2, RBMY1F, PRY, AMELY,
TTTY11, TTTY14, TTTY10, TTTY13, TTTY5.
Found at: doi:10.1371/journal.pone.0009104.s002 (5.50 MB TIF)
Table S1 Differentially expressed genes overlapping among 3
PD microarray datasets. Listed are genes differentially expressed
by 1.2 fold (p,.05 with no multiple correction) in any 2 of the 3
PD public datasets analyzed.
Found at: doi:10.1371/journal.pone.0009104.s003 (0.04 MB
XLS)
Table S2 Transcripts with differential exonic expression in PD
blood. Affymetrix Exon_ST1 arrays showed 218 transcripts with
significant change (p,0.05 with Benjamini Hochberg FDR
correction) in exonic expression in 17 PD blood samples versus
11 healthy controls.
Found at: doi:10.1371/journal.pone.0009104.s004 (0.24 MB
DOC)
Table S3 Transcripts with significant exonic expression in PD
blood show over- representation of Protein Binding Gene
Ontology (GO) function. 112/218 transcripts with significant
change in exonic expression in 17 PD blood samples versus
healthy 11 controls belong to the GO Biological Function Protein
Binding.
Found at: doi:10.1371/journal.pone.0009104.s005 (0.12 MB
DOC)
Table S4 Genes differentially regulated by at least 2.0 fold in PD
blood. 58 genes were differerntially expressed (FC .=2.0; p,.05
with no multiple correction) in the blood of 17 PDs versus 11
controls.
Found at: doi:10.1371/journal.pone.0009104.s006 (0.03 MB
XLS)
Table S5 Characteristics of our PD cohort included in our Real-
Time PCR analysis. M= Male, F= Female, A–R= Akinetic-
Rigid dominant PD, Tremor= Tremor dominant PD, HY=
Hoehn and Yahr Parkinson’s disease stage, PMI= post-mortem
interval.
Found at: doi:10.1371/journal.pone.0009104.s007 (0.05 MB
DOC)
Table S6 Characteristics of our PD and control cohort included
in our Affymetrix Exon Arrays and TaqMan Low Density Arrays.
Control and PD subjects were recruited for our study. The best
quality blood RNA used on the arrays came from 17 PDs and 11
controls.
Found at: doi:10.1371/journal.pone.0009104.s008 (0.03 MB
XLS)
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